Roche/Syntex
This article was originally published in The Gray Sheet
Executive Summary
Roche's $5.3 bil. acquisition of Syntex is completed Sept. 1 after Roche agrees to divest within a year the U.S. portion of Syntex' Syva diagnostics subsidiary. The Federal Trade Commission, which made its approval of the acquisition conditional on Roche's divestiture of Syva, said it was concerned that combining Roche and Syva's drugs of abuse testing businesses "could substantially lessen competition in" that market "or tend to create a monopoly...or enhance the likelihood of collusion in the market." Drug screening and monitoring assays are a major portion of Syva's business, which also includes infectious disease diagnostics and immunodiagnostics. Syva had sales of $212 mil. in 1993
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.